Molecular imaging of in vivo gene expression

Future Medicinal Chemistry

Volumn 2, Issue 3, 2010, Pages 503-519

  Harney, Allison S ^a   Meade, Thomas J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; BETA LACTAMASE; CASPASE 3; CONTRAST MEDIUM; FERRITIN; GELATINASE A; GREEN FLUORESCENT PROTEIN; LUCIFERASE; METALLOPROTEIN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PROTEASOME; PROTEINASE; YELLOW FLUORESCENT PROTEIN;

BIOLUMINESCENCE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CANCER DIAGNOSIS; CELL FUNCTION; CELL MATURATION; CHEMOLUMINESCENCE; CONTRAST ENHANCEMENT; ENZYME ACTIVITY; FETUS HEART; FETUS LIVER; FLUORESCENCE IMAGING; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION; GENE PROBE; GENETIC TRANSCRIPTION; HUMAN; INFRARED RADIATION; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; REPORTER GENE; REVIEW; TREATMENT PLANNING; TUMOR GROWTH; VIRUS INFECTION;

ANIMALS; CONTRAST MEDIA; FLUORESCENT DYES; GENE EXPRESSION; GENES, REPORTER; LUMINESCENCE; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; MOLECULAR STRUCTURE;

EID: 77953455646     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.168     Document Type: Review

References (153)

1. Collins FS, Mckusick VA. Implications of the human genome project for medical science. JAMA 285(5), 540-544 (2001).
2. Piwnica-Worms DR. Introduction to molecular imaging. J. Am. Coll. Radiol. 1(1 Suppl. 1), 2-3 (2004).
3. Meade TJ. Seeing is believing. Acad. Radiol. 8(1), 1-3 (2001).
4. Cho S-M, Ha HK, Byun JY et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. Am. J. Roentgenol. 179(2), 391-395 (2002).
5. 3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13(22 Pt 1), 6610-6616 (2007).
6. Wong FC, Kim EE. A review of molecular imaging studies reaching the clinical stage. Eur. J Radiol. 70(2), 205-211 (2009).
7. Linden HM, Stekhova SA, Link JM et al. Quantitative fluoroestradiol: positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J. Clin. Oncol. 24(18), 2793-2799 (2006).
8. 18F-FDG. J. Nucl. Med. 49(1), 22-29(2008).
9. Weissleder R, Mahmood U. Molecular imaging. Radiology 219(2), 316-333 (2001).
10. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat. Rev. Cancer 2(1), 11-18 (2002).
11. Tsien RY. Imagining imaging's future, Nat. Rev. Mol. Cell Biol. (Suppl.), SS16-SS21 (2003).
12. Ntziachristos V, Bremer C, Graves EE, Ripoll J, Weissleder R. In vivo tomographic imaging of near-infrared fluorescent probes, Mol. Imaging 1(2), 82-88 (2002).
13. Ripoll J, Nieto-Vesperinas M, Weissleder R, Ntziachristos V. Fast: analytical approximation for arbitrary geometries in diffuse optical tomography. Opt. Lett. 27(7), 527-529 (2002).
14. Nowotschin S, Eakin GS, Hadjantonakis AK. Live-imaging fluorescent proteins in mouse embryos: multi-dimensional, rnulti-spectral perspectives. Trends Biotechnol. 27(5), 266-276 (2009).
15. Quaresima V, Matcher SJ, Ferrari M. Identification and quantification of intrinsic optical contrast: for near-infrared mammography. Photochem. Photobiol. 67(1), 4-14 (1998).
16. Kahraman S, Dirice E, Sanlioglu AD et al. In vivo fluorescence imaging is well-suited for the monitoring of adenovirus directed transgene expression in living organisms, Mol. Imaging Biol. (2009) (Epub ahead of print).
17. Oshiro M, Moomaw B. Cooled vs. intensified vs. electron bombardment CCD cameras - applications and relative advantages. In: Methods in Cell Biology (Volume 72). Academic Press, NY, USA, 133-156 (2003).
18. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur. Radiol. 13(1), 195-208 (2003).
19. Miontet X, Ntziachristos V, Grimm J, Weissleder R. Tomographic fluorescence mapping of tumor targets. Cancer Res. 65(14), 6330-6336 (2005).
20. Graves EE, Ripoll J, Weissleder R, Ntziachristos V. A submillimeter resolution fluorescence molecular imaging system for small animal imaging. Med. Phys. 30(5), 901-911 (2003).
21. Ntziachristos V, Tung Ch, Bremer C, Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat. Med. 8(7), 757-760 (2002).
22. Ntziachristos V, Yodh AG, Schnall M, Chance B. Concurrent MRI and diffuse optical tomography of breast after iridocyanine green enhancement. Proc. Natl Acad. Sci. USA 97(6), 2767-2772 (2000).
23. Taroni P, Pifferi A, Torricelli A, Comelli D, Cubeddu R. In vivo absorption and scattering spectroscopy of biological tissues. Photochem. Photobiol. Sci. 2(2), 124 129 (2003).
24. Schick F. Whole-body MRI at high field: technical limits and clinical potential. Eur. Radiol. 15(5), 946-959 (2005).
25. Tyszka JM, Fraser SE, Jacobs RE. Magnetic resonance microscopy: recent advances and applications, Curr. Opin. Biotechnol. 16(1), 93-99 (2005).
26. Smirnov P, Poirier-Quinot M, Wilhelm C et al. In vivo single cell detection of tumor-infiltrating lymphocytes with a clinical 1.5 Tesla MRI system. Magn. Res. Med. 60(6), 1292-1297 (2008).
27. Sigurdsson EM, Wadghiri Y'Z, Mosconi I. et al. A. non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol. Aging29(6), 836-847 (2008).
28. Lee S-C, Mietchen D, Cho J-Hi et al. In vivo magnetic resonance microscopy of differentiation in Xenopus lands embryos from the first cleavage onwards. Differentiation 75(1), 84-92 (2007).
29. Glover P, Mansfield SP. Limits to magnetic resonance microscopy. Reports Progr. Phys. 65, 1489-1511 (2002).
30. Jacoby C, Boring YC, Beck A et al. Dynamic changes in murine vessel geometry assessed by high-resolution magnetic resonance angiography: a 9.4T study, J. Magn. Res. Imaging28(3), 637-645 (2008).
31. Modo M, Mellodew K, Cash D et al. Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study. Neurolmage 21(1), 311-317 (2004).
32. Louie AY, Huber MM, Ahrens ET et al. In vivo visualization of gene expression using magnetic resonance imaging, Nat. Biotech. 18(3), 321-325 (2000).
33. Belayev L, Obenaus A, Zhao W et al. Experimental intracerebral hematoma in the rat: characterization by sequential magnetic resonance imaging, behavior, and histopathology. Effect of albumin therapy. Brain Res. 1157,146-155 (2007).
34. Cherry SR. In vivo molecular and genomic imaging: new challenges for imaging physics, Phys. Med. Biol. 49(3), R13-R48 (2004).
35. Dodd SJ, Williams M, Suhan JP, Williams DS, Koretsky AP, Ho C. Detection of single mammalian cells by high-resolution magnetic resonance imaging. Biophys. J. 76(1), 103-109 (1999).
36. Caravan P, Ellison JJ, Mcmurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 99(9), 2293-2352 (1999).
37. 1 contrast agents. Contrast Media Mol. Imaging 4(2), 89-100 (2009).
38. Mahmood U, Weissleder R. Near-infrared optical imaging of proteases in cancer. Mol. Cancer Ther. 2(5), 489-496 (2003).
39. Kang JH, Chung J-K. Molecular-genetic imaging based on reporter gene expression. J. AW. Med. 49(Suppl. 2), 164S-179S (2008).
40. Song Y, Kohlmeir EK Meade TJ. Synthesis of multimeric MR contrast agents for cellular imaging. J. Am. Chem. Soc. 130(21), 6662-6663 (2008).
41. de Sousa PL, Livramento JB, Helm I. et al. In vivo MRI assessment of a novel Gd(III)based contrast agent designed, for high magnetic field applications. Contrast Media Mol. Imaging3(2), 78-85 (2008).
42. Caravan P, Cloutier NJ, Greenfield MT et al. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J. Am. Chem. Soc. 124(12), 3152-3162 (2002).
43. Gross S, Piwnica-Worms D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell7(1), 5-15 (2005).
44. Massoud TF, Paulmurugan R, De A, Ray P, Gambhir SS. Reporter gene imaging of protein-protein interactions in living subjects. Curr. Opin. Biotechnol. 18(1), 31-37 (2007).
45. Villalobos V, Naik S, Piwnica-Worms D. Current state of imaging protein-protein interactions in vivo with genetically encoded reporters. Annu. Rev. Biomed. Eng. 9, 321-349 (2007).
46. Prasher DC, Eckenrode VK, Ward WW, Prendergast FG, Cormier MJ. Primary structure of the aequorea victoria greenfluorescent protein. Gene 111(2), 229.....233 (1992).
47. Griesbeck O, Baird GS, Campbell RE, Zacharias DA, Tsien RY. Reducing the environmental sensitivity of yellow fluorescent protein: mechanism and applications.J. Biol. Chem. 276(31), 29188-29194 (2001).
48. Heim R, Prasher DC, Tsien RY. Wavelength mutations and posttranslational autoxidation of green fluorescent protein. Proc. Natl Acad. Sci. USA 91(26), 12501-12504 (1994).
49. Heim. R, Tsien RY. Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer. Curr. Biol. 6(2), 178-182 (1996).
50. Rizzo MA, Springer GH, Granada B, Piston DW An improved cyan fluorescent protein variant useful for fret, Nat Biotechnol. 22(4), 445-449 (2004).
51. Nowotschin S, Eakin GS, Hadjantonakis A-K. Dual transgene strategy for live visualization of chromatin and plasma membrane dynamics in murine embryonic stem cells and embryonic tissues, Genesis 47(5), 330-336 (2009).
52. Chudakov DM, Lukyanov S, Lukyanov KA. Fluorescent proteins as a toolkit for in vivo imaging. Trends Biotechnol. 23(12), 605-613 (2005).
53. Mizuno H, Sawano A, Eli P, Hama H, Miiyawaki A. Red fluorescent protein from, discosoma as a fusion tag and a partner for fluorescence resonance energy transfer. Biochemistry 40(8), 2502-2510 (2001).
54. Shaner NC, Steinbach PA, Tsien RY. A guide to choosing fluorescent proteins. Nat. Meth. 2(12), 905-909 (2005).
55. Shaner NC, Campbell RE, Steinbach PA, Giepmans BNG, Palmer AE, Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived, from Discosoma sp. red fluorescent protein. Nat. Biotech. 22(12), 1567-1572 (2004).
56. Deliolanis NC, Kasmieh R, Wurdinger T, Tannous BA, Shah K, Ntziachristos V. Performance of the red-shifted fluorescent proteins in deep-tissue molecular imaging applications. J. Biomed. Optics 13(4), 44008-44009 (2008).
57. Truong K, Ikura M. The use of FRET imaging microscopy to detect: proteinprotein interactions and protein conformational changes in vivo. Curr. Opin. Struct. Biol. 11(5), 573-578 (2001).
58. Didenko VV. DNA probes using fluorescence resonance energy transfer (FRET): designs and applications, Biotechniques 31(5), 1106-1121 (2001).
59. Forster T. Transfer mechanisms of electronic excitation energy, Radiat. Res. (Suppl. 2), 326-339 (1960).
60. Wu PG, Brand L. Resonance energy transfer: methods and applications, Anal. Biochem. 218(1), 1-13 (1994).
61. Mitra RD, Silva CM, Youvan DC. Fluorescence resonance energy transfer between blue-emitting and red-shifted excitation derivatives of the green fluorescent protein, Gene 173(1), 13-17 (1996).
62. Kamiyama D, Chiba A. Endogenous activation patterns of CDC42 GT Pase within drosophila embryos. Science 324(5932), 1338-1340 (2009).
63. Chan FK, Siegel RM, Zacharias D et al. Fluorescence resonance energy transfer analysis of cell surface receptor interactions and signaling using spectral, variants of the green fluorescent protein. Cytometry 44(4), 361-368(2001).
64. Pollok BA, Heim R. Using GFP in FRETbased applications. Trends Cell Biol. 9(2), 57-60 (1999).
65. 2+ based, on green fluorescent proteins and calmodulin. Nature 388(6645), 882-887(1997).
66. Hara M, Bindokas V, Lopez JP et al. Imaging endoplasmic reticulum calcium with a fluorescent biosensor in transgenic mice, Am. J. Physiol. Cell Physiol. 287(4), C932-C938 (2004).
67. Higashijima S-I, Masino MA, Mandel G, Fetcho JR. Imaging neuronal activity during zebrafish behavior with a genetically encoded, calcium indicator. J. Neurophysiol. 90(6), 3986-3997 (2003).
68. Kerr R, Lev-Ram V, Baird G, Vincent P, Tsien RY, Schafer WR. Optical imaging of calcium, transients in neurons and pharyngeal muscle of C. elegans. Neuron 26(3), 583-594 (2000).
69. Tyas L, Brophy VA, Pope A, Rivett AJ, Tavare JM. Rapid caspase-3 activation during apoptosis revealed using fluorescenceresonance energy transfer. EMBO Rep. 1(3), 266-270 (2000).
70. Zhou F, Xing D, Wu S, Chen WR. Intravital imaging of tumor apoptosis with FRET probes during tumor therapy. Mol. Imaging Biol. 12(1), 63-70 (2010).
71. Sato A, Klaunberg B, Tolwani R. In vivo bioluminescence imaging. Comp. Med. 54(6), 631-634 (2004).
72. Fraga H. Firefly luminescence: a historical perspective and recent developments. Photochem. Photobiol. Sci. 7(2), 146-158 (2008).
73. McElroy WD, Seliger HH, White EH. Mechanism of bioluminescence, chemiluminescerice and enzyme function in the oxidation of firefly luciferin. Photochem. Photobiol. 10(3), 153-170 (1969).
74. Lorenz WW, Cormier MJ, O'Kane DJ, Hua D, Escher AA, SzalayAA. Expression of the Renilla reniformis luciferase gene in mammalian cells. J. Biolumin. Chemilumin. 11(1), 31-37 (1996).
75. Bhaumik S, Gambhir SS. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc. Natl Acad. Sci. USA 99(1), 377-382 (2002).
76. Contag CH, Bachmann MH. Advances in in vivo bioluminescence imaging of gene expression. Annu. Rev. Biomed. Eng. 4, 235-260 (2002).
77. Ma L, Xiang Z, Sherrill TP et al. Bioluminescence imaging visualizes activation of nuclear factor-KB in mouse cardiac transplantation. Transplantation 85(6), 903-910 (2008).
78. de Wet JR, Wood KV, DeLuca M, Helinski DR, Subramani S. Firefly luciferase gene: structure and expression in mammalian cells. Mol. Cell. Biol. 7(2), 725-737 (1987).
79. Leo BM, Li X, Balian G, Anderson DG. In vivo bioluminescent imaging of virusmediated gene transfer and transduced cell transplantation in the intervertebral disc. Spine (Phila. PA. 1976) 29(8), 838-844 (2004).
80. 14C-D-luciferin - a radiolabeled substrate for the firefly luciferase catalyzed bioluminescence reaction: impact on bioluminescence based reporter gene imaging. Eur. J. Nucl. Med. Mol. Imaging 35(12), 2275-2285 (2008).
81. Contag CH, Contag PR, Mullins JI, Spilman SD, Stevenson DK, Benaron DA. Photonic detection of bacterial pathogens in living hosts. Mol. Microbiol. 18(4), 593-603 (1995).
82. Hutchens M, Luker GD. Applications of bioluminescence imaging to the study of infectious diseases, Cell. Microbiol. 9(10), 2315-2322 (2007).
83. Mook-Kaiiarnori B, Rouse M, Kang C-I, Van De Beek D, Steckelberg J, Patel R. Daptomycin in experimental murine pneumococcal meningitis. BMC Infect. Dis. 9(1), 50 (2009).
84. Thorn RMS, Nelson SM, Greenman J. Use of a bioluminescent Pseudomonas aeruginosa strain within an in vitro microbiological system, as a model of wound, infection, to assess the antimicrobial efficacy of wound, dressings by monitoring light production, Antimicrob. Agents Chemother. 51(9), 3217-3224 (2007).
85. Dothager RS, Flentie K, Moss B, Pan M-H, KesarwalaA, Piwnica-Worms D. Advances in bioluminescence imaging of live animal models. Curr. Opin. Biotechnol. 20(1), 45-53 (2009).
86. Luker KE, Luker GD. Applications of bioluminescence imaging to antiviral research and therapy: multiple luciferase enzymes and quantitation. Antiviral Res. 78(3), 179-187 (2008).
87. Luker GD, Bardill JP, Prior JL, Pica CM, Piwnica-Worms D, Leib DA. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J. Virol. 76(23), 12149-12161 (2002).
88. Mizuno T, Mohri K, Nasu S, Danjo K, Okamoto H. Dual, imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bioluminescence, J. Control. Release 134(2), 149-154 (2009).
89. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection, Mol. Ther. 16(6), 1073-1080(2008).
90. Klerk CP, Overmeer RM, Niers TM et al. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques 43(1 Suppl.), 7-13, 30(2007).
91. Scatena CD, Hepner MA, Oei YA et al. Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer. Prostate 59(3), 292-303 (2004).
92. Paroo Z, Bollinger RA, Braasch DA et al. Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol. Imaging3(2), 117-124(2004).
93. Wetterwald A, Van Der Pluijm G, Que I et al. Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am. J.Pathol. 160(3), 1143-1153 (2002).
94. Shi HY, Liang R, Templeton NS, Zhang M. Inhibition of breast tumor progression by systemic delivery of the maspin gene in a syngeneic tumor model. Mol. Ther. 5(6), 755-761 (2002).
95. Zhang M, Sheng S, Maass N, Sager R. Maspin: the mouse homolog of a human tumor suppressor gene inhibits mammary tumor invasion and motility, Mol. Med. 3(1), 49-59 (1997).
96. Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA, Dong Z. Blocking activator protein-1 activity, but not activating retinoic acid, response element, is required, for the antitumor promotion effect of retinoic acid. Proc. Natl Acad. Sci. USA 94(11), 5826-5830 (1997).
97. Laxman B, Hall DE, Bhojani MS et al. Noninvasive real-time imaging of apoptosis. Proc. Natl Acad. Sci, USA 99(26), 16551-16555 (2002).
98. Petroski MD. The ubiquitin system, disease, and drug discovery. BMC Biochem 9(Suppl. 1), S7(2008).
99. Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. Proteasome inhibitor therapy in multiple myeloma, Mol. Cancer Ther. 4(4), 686-692 (2005).
100. Kimbrel EA, Davis TN, Bradner JE, Kung AL. In vivo pharmacodynamic imaging of proteasome inhibition. Mol. Imaging8(3), 140-147 (2009).
101. Kesarwala AH, Samrakandi MM, Piwnica-Worms D. Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation. Cancer Res. 69(3), 976-983 (2009).
102. Luker GD, Pica CM, Song J, Luker KE, Piwnica-Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nat. Med. 9(7), 969-973(2003).
103. Xu Y, Piston DW, Johnson CH. A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins. Proc. Natl Acad. Sci. USA 96(1), 151-156(1999).
104. Koterba KL, Rowan BG. Measuring ligand-dependent and ligand-independent interactions between nuclear receptors and associated proteins using bioluminescence resonance energy transfer (BRET). Nucl. Recept. Signal. 4, e021 (2006).
105. De A, Ray P, Loening AM, Gambhir SS. BRET3: a red-shifted bioluminescence resonance energy transfer (BRET)-based integrated platform for imaging protein-protein interactions from, single live cells and living animals, FASEB J. 23, 2702-2709 (2009).
106. De A, Loening AM, Gambhir SS. An improved, bioluminescence resonance energy transfer strategy for imaging intracellular events in single cells and living subjects. Cancer Res. 67(15), 7175-7183 (2007).
107. 2+. J. Biomed. Opt. 13(3), 031211 (2008).
108. Iglesias P, Costoya JA. A novel BRET-based genetically encoded, biosensor for functional imaging of hypoxia. Biosens. Bioelectron. 24(10), 3126-3130(2009).
109. Lee K-H, Byun SS, Paik J-Y Vral. Cell uptake and tissue distribution of radioiodine labelled D-luciferin: implications for luciferase based gene imaging, Nucl. Med. Commun. 24(9), 1003-1009 (2003).
110. Shindc R, Perkins J, Contag CH. Luciferin derivatives for enhanced in vitro and in vivo bioluminescence assays. Biochemistry 45(37), 11103.....11112(2006).
111. Seemann MD. Whole-body PET/MRI: the future in oncological imaging, Technol. Cancer Res. Treat. 4(5), 577-582 (2005).
112. Gilad AA, Winnard PT Jr, Van Zijl PCM, Bulte JWM. Developing MR reporter genes: promises and pitfalls. NMR Biomed. 20(3), 275-290 (2007).
113. Cohen B, Ziv K, Plaks V, Harmelin A, Neeman M. Ferritin nanoparticles as magnetic resonance reporter gene. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1(2), 181-188(2009).
114. St Pierre TG, Chan P, Bauchspiess KR et al. Synthesis, structure and magnetic properties of ferritin cores with varying composition and degrees of structural order: models for iron oxide deposits in iron-overload diseases, Coord. Chem, Rev. 151, 125 143 (1996).
115. Genove G, Demarco U, Xu H, Coins WF, Ahrens ET. A new transgene reporter for in vivo magnetic resonance imaging. Nat. Med. 11(4), 450-454(2005).
116. Cohen B, Ziv K, Plaks V et al. MRI detection of transcriptional regulation of gene expression in transgenic mice. Nat. Med. 13(4), 498-503 (2007).
117. Bartzokis G, Aravagiri M, Oldendorf WH, Mintz J, Marder SR. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magn. Reson. Med. 29(4), 459-464 (1993).
118. Deans AE, Wadghiri YZ, Bernas LM, Yu X, Rutt BK, Turnbull DH. Cellular MRI contrast via coexpression of transferrin receptor and ferritin. Magn. Reson. Med. 56(1), 51-59 (2006).
119. Arosio P, Levi S. Ferritin, iron homeostasis, and oxidative damage. Free Radie. Biol. Med. 33(4), 457-463 (2002).
120. Zurkiya O, Chan AW, Hu X. MiagA is sufficient for producing magnetic nanoparticles in mammalian cells, making it an MRI reporter. Magn. Reson. Med. 59(6), 1225-1231 (2008).
121. Watson CM, Trainor PA, Radziewic T et al. Application of Lac Z transgenic mice to cell lineage studies. Methods Mol. Biol. 461, 149-164 (2008).
122. Bogdanov A, Weissleder R. In vivo imaging of gene delivery and expression. Trends Biotechnol. 20(8), S11-Sl8 (2002).
123. Moats RA, Fraser SE, Meade TJ. A 'smart' magnetic resonance imaging agent that reports on specific enzymatic activity. Angew. Chem. Int. Ed. Eng. 36(7), 726-728 (1997).
124. Urbanczyk-Pearson LM, Femia FJ, Smith J et al. Mechanistic investigation of ß-galactosidase-activated MR contrast agents, Inorg. Chem. 47(1), 56-68 (2008).
125. Urbanczyk-Pearson LM, Meade TJ. Preparation of magnetic resonance contrast agents activated by ß-galactosidase, Nat. Protoc. 3(3), 341-350 (2008).
126. Alauddin MM, Louie AY, Shahinian A, Meade TJ, Conti PS. Radiolabeling of a MRI contrast agent with In-111, and its biological evaluation in vitro and in vivo. J Nucl. Med. 43(5), 503 (2002).
127. Alauddin MM, Louie AY, Shahinian A, Meade TJ, Conti PS. Receptor mediated uptake of a radiolabeled contrast agent sensitive to ß-galactosidase activity. Nucl. Med. Biol. 30(3), 261-265 (2003).
128. 2O)] for tracing gene expression. Bioconjug. Chem. 18(6), 1716-1727 (2007).
129. Tung C-H, Zeng Q, Shah K, Kim. D-E, Schellingerhout D, Weissleder R. In vivo imaging of {ß}-galactosidase activity using far red fluorescent switch. Cancer Res. 64(5), 1579-1583 (2004).
130. Josserand V, Texier-Nogues I, Huber P, Favrot MC, Coll JL. Non-invasive in vivo optical imaging of the lacZ and lue gene expression in mice, Gene Ther. 14(22), 1587-1593 (2007).
131. Zhang G-J, Chen T-B, Connolly B et al. In vivo optical imaging of lacZ expression using lacZ transgenic mice, ASSAYDrug Develop. Technol. 7(4), 391-399 (2009).
132. Corey PF, Trimmer RW, Biddlecom WG. A. new chromogenic ß-galactosidase substrate: 7-ß-D-galactopyra.nosyloxy-9,9-dimethyl- 9H-acridin-2-one. Angew. Chem. Int. Ed. Eng. 30(12), 1646-1648 (1991).
133. Wehrman TS, Von Degenfeld G, Krutzik PO, Nolan GP, Blau HM. Luminescent imaging of ß-galactosidase activity in living subjects using sequential reporter-enzyme luminescence. Nat. Meth. 3(4), 295-301 (2006).
134. Yao H, So MK, Rao J. A bioluminogenic substrate for in vivo imaging of ß-lactamase activity, Angew. Chem. Int. Ed. Engl. 46(37), 7031-7034 (2007).
135. Zlokarnik G, Negulescu PA, Knapp TE et al. Quantitation of transcription and clonal selection of single living cells with p-lactamase as reporter. Science 279(5347), 84 (1998).
136. Xing B, Khanariiiryan A, Rao J. Cellpermeable near-infrared fluorogenic substrates for imaging ß-lactamase activity, J.Am. Chem. Soc. 127(12),4158-4159 (2005).
137. Lee S, Park K, Kim K, Choi K, Kwon IC. Activatable imaging probes with amplified fluorescent signals. Chem. Commun. (Camb.) 36,4250-4260(2008).
138. Maxwell D, Chang Q, Zhang X, Barnett EM, Piwnica-Worms D. An improved cellpenetrating, caspase-activatable, near-infrared fluorescent peptide for apoptosis imaging. Bioconjug. Chem. 20(4), 702-709 (2009).
139. Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev. 27(4), 655-664 (2008).
140. Ke S, Wen X, Gurfinkel M et al. Nearinfrared optical imaging of epidermal growth factor receptor in breast cancer xenografts, Cancer Res. 63(22), 7870-7875 (2003).
141. Stearns Me, Wang M. Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 53(4), 878-883 (1993).
142. Hu L, Roth JM, Brooks P, Luty J, Karpatkin S. Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and. metastasis, Cancer Res. 68(12), 4666-4673 (2008).
143. Hotary K, Allen E, Punturieri A, Yana I, Weiss SJ. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J. Cell Biol. 149(6), 1309-1323 (2000).
144. Whittaker M, Floyd CD, Brown P, Gearing AJH. Design and therapeutic application of matrix metalloproteinase inhibitors, Chem, Rev. 99(9), 2735-2776 (1999).
145. Kato D, Boatright KM, Berger AB et al. Activity-based probes that target diverse cysteine protease families. Nat. Chem. Biol. 1(1), 33-38 (2005).
146. Blum G, Von Degenfeld G, Merchant MJ, Blau HM, Bogyo M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat. Chem. Biol. 3(10), 668-677 (2007).
147. Greish K. Enhanced permeability and. retention of macromolecular drugs in solid tumors: a royal, gate for targeted anticancer nanomedicines, J. Drug Target. 15(7-8), 457-464 (2007).
148. Weissleder R, Tung CH, Mahmood U, Bogdanov A Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes, Nat. Biotechnol. 17(4), 375-378 (1999).
149. Tung CH, Mahmood U, Bredow S, Weissleder R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res. 60(17), 4953-4958 (2000).
150. Bremer C, Ntziachristos V, Weitkamp B, Theilmeier G, Heindel W, Weissleder R. Optical imaging of spontaneous breast tumors using protease sensing 'smart' optical probes, Invest. Radiol. 40(6), 321-327 (2005).
151. Bremer C, Tung C-H, Weissleder R. In vivo molecular target: assessment of matrix metalloproteinase inhibition. Nat. Med. 7(6), 743-748 (2001).
152. Jastrzebska B, Lebel R, Mclntyre OJ et al. Monitoring of MMPs activity in vivo, non-invasively, using solubility switchable MRI contrast agent. Adv. Exp. Med. Biol. 611, 453-454 (2009).
153. Lebel R, Jastrzebska B, Therriault H et al. Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model. Magn. Reson. Med. 60(5), 1056-1065 (2008).